The groundbreaking success of Sildenafil undeniably reshaped the drug landscape, but placing funds in companies heavily reliant on generic versions presents a challenging picture. Despite early profits were impressive, the end of patents and the rise of less expensive alternatives have weakened the customer base. Therefore, a thorough analysis of o